Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
Company Awards $1.8M in Grants to Eight Organizations in Brazil, India, Thailand and the United KingdomOriginally published on Bristol Myers...
Clinical Trial
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024ELI-007 and ELI-008 preclinical...
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company...
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities...
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results...
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or...
BioSenic S.A. : Information on the total number of voting rights and shares
PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, March 29, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS),...
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a...
Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update
Company to host investor call and webcast on Monday, April 1st, at 8:30am EDTPITTSBURGH, March 28, 2024 (GLOBE NEWSWIRE) --...
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results
GUANGZHOU, China, March 28, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or...
Sirona Biochem Announces 2023 Annual Meeting Results
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces...
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
Launch of OLPRUVA® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4...
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline...
NervGen Completes $23 Million Bought Deal Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.Vancouver, British Columbia--(Newsfile Corp. -...
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
Medical oncologist brings over 25 years of industry experience to lead Clinical Development StrategyBOSTON, March 28, 2024 (GLOBE NEWSWIRE) --...
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing...
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital $50 million financing upfront...
Dyadic Announces Change in Board and Management Leadership Roles
JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),...
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart...